News
RLAY
15.26
+2.14%
0.32
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines
Reuters · 36m ago
RELAY THERAPEUTICS INC <RLAY.O>: JONESTRADING INITIATES COVERAGE WITH HOLD RATING; TARGET PRICE $18
Reuters · 5h ago
Relay Therapeutics initiated with a Hold at JonesResearch
TipRanks · 12h ago
Top and lowest-rated mid-cap stocks heading into earnings
Seeking Alpha · 18h ago
Weekly Report: what happened at RLAY last week (0406-0410)?
Weekly Report · 22h ago
Relay CFO Thomas Catinazzo disposes of Relay Therapeutics shares worth $257,775
Reuters · 4d ago
RLAY Hits 52-Week High, MPLT Nears Lockup Expiry; ORKA Makes EVERLASTing Gains
NASDAQ · 4d ago
Relay Therapeutics Is Maintained at Overweight by Barclays
Dow Jones · 5d ago
Relay Therapeutics Price Target Raised to $21.00/Share From $17.00 by Barclays
Dow Jones · 5d ago
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $21
Benzinga · 5d ago
RELAY THERAPEUTICS INC. <RLAY.O>: BARCLAYS RAISES TARGET PRICE TO $21 FROM $17
Reuters · 5d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 6d ago
Healthcare quant check: RLAY and TNGX lead Seeking Alpha’s top picks ahead of Q1 earnings
Seeking Alpha · 6d ago
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
NASDAQ · 04/06 13:11
Weekly Report: what happened at RLAY last week (0330-0403)?
Weekly Report · 04/06 09:58
Relay to present initial clinical data for zovegalisib in vascular anomalies at ISSVA 2026
Reuters · 04/02 20:08
Relay Therapeutics To Present Initial Clinical Results, Preclinical Data For Zovegalisib In Vascular Anomalies At International Society For The Study Of Vascular Anomalies World Congress 2026
Benzinga · 04/02 20:07
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 04/02 17:05
Weekly Report: what happened at RLAY last week (0323-0327)?
Weekly Report · 03/30 09:58
Relay Therapeutics Price Target Raised to $19.00/Share From $14.00 by HC Wainwright & Co.
Dow Jones · 03/23 11:25
More
Webull provides a variety of real-time RLAY stock news. You can receive the latest news about Relay Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.